ALDX logo

Aldeyra Therapeutics, Inc.

ALDX

ALDX: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

more

Show ALDX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ALDX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by ALDX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods of treating retinal disease Aug. 15, 2023
  • Patent Title: Toxic aldehyde related diseases and treatment Jul. 18, 2023
  • Patent Title: Treatment of inflammatory disorders Feb. 21, 2023
  • Patent Title: Deuterated compounds and uses thereof Oct. 04, 2022
  • Patent Title: Polymorphic compounds and uses thereof Apr. 26, 2022
  • Patent Title: Formulations for treatment of dry eye disease Dec. 14, 2021
  • Patent Title: Combination treatment of ocular inflammatory disorders and diseases Sep. 28, 2021
  • Patent Title: Deuterated compounds and uses thereof Jun. 29, 2021
  • Patent Title: Treatment of inflammatory disorders Jun. 22, 2021
  • Patent Title: Toxic aldehyde related diseases and treatment May. 18, 2021
  • Patent Title: Compositions and methods of treating retinal disease Feb. 09, 2021
  • Patent Title: Toxic aldehyde related diseases and treatment Mar. 17, 2020
  • Patent Title: Deuterated compounds and uses thereof Feb. 04, 2020
  • Patent Title: Toxic aldehyde related diseases and treatment Jan. 28, 2020
  • Patent Title: Treatment of allergic eye conditions with cyclodextrins Oct. 01, 2019
  • Patent Title: Polymorphic compounds and uses thereof Sep. 17, 2019
  • Patent Title: Toxic aldehyde related diseases and treatment Feb. 26, 2019
  • Patent Title: Compositions and methods of treating retinal disease Feb. 12, 2019
  • Patent Title: Traps in the treatment of macular degeneration Oct. 30, 2018
  • Patent Title: Compositions and methods of treating retinal disease Feb. 20, 2018
  • Patent Title: Compositions and methods for the treatment of macular degeneration Nov. 14, 2017
  • Patent Title: Toxic aldehyde related diseases and treatment Jun. 27, 2017
  • Patent Title: Compositions and methods of treating retinal disease May. 16, 2017
  • Patent Title: Peri-carbinols Mar. 28, 2017
  • Patent Title: Compositions and methods of treating retinal disease Jun. 14, 2016
  • Patent Title: Compositions and methods of treating retinal disease Feb. 23, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ALDX in WallStreetBets Daily Discussion

ALDX News

Recent insights relating to ALDX

CNBC Recommendations

Recent picks made for ALDX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALDX

Corporate Flights

Flights by private jets registered to ALDX